SCT recruits first patient in TBI drug trial
The trial aims to characterize the safety profile of NTx-428 when administered to patients who have sustained a TBI. The company expects to complete the recruitment of 10
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.